The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Elucidation of CXCR7-Mediated Signaling Events and Inhibition of CXCR4-Mediated Tumor Cell Transendothelial Migration by CXCR7 Ligands
Open accessAbstract
CXCR7 binds chemokines CXCL11 (I-TAC) and CXCL12 (SDF-1) but does not act as a classical chemoattractant receptor. Using CCX771, a novel small molecule with high affinity and selectivity for CXCR7, we found that, although CXCR7 is dispensable for “bare filter” in vitro chemotaxis, CXCR7 plays an essential role in the CXCL12/CXCR4-mediated transendothelial migration (TEM) of CXCR4+CXCR7+ human tumor cells. Importantly, although CXCL11 is unable to stimulate directly the migration of these cells, it acts as a potent antagonist of their CXCL12-induced TEM. Furthermore, even though this TEM is driven by CXCR4, the CXCR7 ligand CCX771 is substantially more potent at inhibiting it than the CXCR4 antagonist AMD3100, which is more than 100 times weaker at inhibiting TEM when compared with its ability to block bare filter chemotaxis. Far from being a “silent” receptor, we show that CXCR7 displays early hallmark events associated with intracellular signaling. Upon cognate chemokine binding, CXCR7 associates with β-arrestin2, an interaction that can be blocked by CXCR7-specific mAbs. Remarkably, the synthetic CXCR7 ligand CCX771 also potently stimulates β-arrestin2 recruitment to CXCR7, with greater potency and efficacy than the endogenous chemokine ligands. These results indicate that CXCR7 can regulate CXCL12-mediated migratory cues, and thus may play a critical role in driving CXCR4+CXCR7+ tumor cell metastasis and tissue invasion. CXCR7 ligands, such as the chemokine CXCL11 and the newly described synthetic molecule CCX771, may represent novel therapeutic opportunities for the control of such cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Burns, J. M., Summers, B. C., Wang, Y., Melikian, A., Berahovich, R., Miao, Z., Penfold, M. E. T., Sunshine, M. J., Littman, D. R., Kuo, C. J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052144 · Cited by 1,263
Self-citationThe Chemokine SDF-1/CXCL12 Binds to and Signals through the Orphan Receptor RDC1 in T Lymphocytes
Balabanian, K., Lagane, B., Infantino, S., Chow, K. Y. C., Harriague, J., Moepps, B., Arenzana-Seisdedos, F., Thelen, M., & Bachelerie, F. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508234200 · Cited by 1,040
Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone.
Taichman, R. S., Cooper, C. R., Keller, E. T., Pienta, K. J., Taichman, N. S., & McCauley, L. K. (2002) · PubMed · Cited by 994
Sierro, F., Biben, C., Martínez-Muñoz, L., Mellado, M., Ransohoff, R. M., Li, M., Woehl, B., Leung, H., Groom, J., Batten, M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702229104 · Cited by 624
Control of Chemokine-Guided Cell Migration by Ligand Sequestration
Boldajipour, B., Mahabaleshwar, H., Kardash, E., Reichman-Fried, M., Blaser, H., Minina, S., Wilson, D., Xu, Q., & Raz, E. (2008) · Cell · doi:10.1016/j.cell.2007.12.034 · Cited by 622
CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling
Levoye, A., Balabanian, K., Baleux, F., Bachelerie, F., & Lagane, B. (2009) · Blood · doi:10.1182/blood-2008-12-196618 · Cited by 613
Miao, Z., Luker, K. E., Summers, B. C., Berahovich, R., Bhojani, M. S., Rehemtulla, A., Kleer, C. G., Essner, J. J., Nasevicius, A., Luker, G. D., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610444104 · Cited by 533
Self-citationSun, Y., Cheng, Z., Ma, L., & Pei, G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207294200 · Cited by 382
Defective lymphocyte chemotaxis in β-arrestin2- and GRK6-deficient mice
Fong, A. M., Premont, R. T., Richardson, R. M., Yu, Y.-R. A., Lefkowitz, R. J., & Patel, D. D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.112198299 · Cited by 311
Valentin, G., Haas, P., & Gilmour, D. (2007) · Current Biology · doi:10.1016/j.cub.2007.05.020 · Cited by 310
AMD3100 Is a CXCR7 Ligand with Allosteric Agonist Properties
Kalatskaya, I., Berchiche, Y. A., Gravel, S., Limberg, B. J., Rosenbaum, J. S., & Heveker, N. (2009) · Molecular Pharmacology · doi:10.1124/mol.108.053389 · Cited by 309
Dambly-Chaudière, C., Cubedo, N., & Ghysen, A. (2007) · BMC Developmental Biology · doi:10.1186/1471-213x-7-23 · Cited by 297
Mazzinghi, B., Ronconi, E., Lazzeri, E., Sagrinati, C., Ballerini, L., Angelotti, M. L., Parente, E., Mancina, R., Netti, G. S., Becherucci, F., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071903 · Cited by 264
Hartmann, T. N., Grabovsky, V., Pasvolsky, R., Shulman, Z., Buss, E. C., Spiegel, A., Nagler, A., Lapidot, T., Thelen, M., & Alon, R. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.0208088 · Cited by 222
CXC chemokines in angiogenesis of cancer
Strieter, R. M., Belperio, J. A., Phillips, R. J., & Keane, M. P. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2003.10.006 · Cited by 218
Shiozawa, Y., Havens, A. M., Pienta, K. J., & Taichman, R. S. (2008) · Leukemia · doi:10.1038/leu.2008.48 · Cited by 211
Broxmeyer, H. E. (2008) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3282f29012 · Cited by 202
Early postnatal lethality and cardiovascular defects in CXCR7‐deficient mice
Gerrits, H., Schenau, D. V. I., Bakker, N. E. C., van Disseldorp, A. J. M., Strik, A., Hermens, L. S., Koenen, T. B., Krajnc-Franken, M. A. M., & Gossen, J. A. (2008) · genesis · doi:10.1002/dvg.20387 · Cited by 164
Hensbergen, P. J., Wijnands, P. G. J. T. B., Schreurs, M. W. J., Scheper, R. J., Willemze, R., & Tensen, C. P. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000165355.26795.27 · Cited by 139
Imaging chemokine receptor dimerization with firefly luciferase complementation
Luker, K. E., Gupta, M., & Luker, G. D. (2008) · The FASEB Journal · doi:10.1096/fj.08-116749 · Cited by 109
Modulation of chemokine receptor activity through dimerization and crosstalk
Salanga, C. L., O’Hayre, M., & Handel, T. M. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8666-1 · Cited by 102
Wise, E. L., Duchesnes, C., da Fonseca, P. C. A., Allen, R. A., Williams, T. J., & Pease, J. E. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703255200 · Cited by 58
CCL2 induces prostate cancer transendothelial cell migration via activation of the small GTPase Rac
van Golen, K. L., Ying, C., Sequeira, L., Dubyk, C. W., Reisenberger, T., Chinnaiyan, A. M., Pienta, K. J., & Loberg, R. D. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21652 · Cited by 55
Buchanan, F. G., & DuBois, R. N. (2006) · Cell Cycle · doi:10.4161/cc.5.18.3212 · Cited by 43
Saita, Y., Kodama, E. N., Orita, M., Kondo, M., Miyazaki, T., Sudo, K., Kajiwara, K., Matsuoka, M., & Shimizu, Y. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.5.3116 · Cited by 33
Identification of CXCR3 receptor agonists in combinatorial small-molecule libraries
Stroke, I. L., Cole, A. G., Simhadri, S. R., Brescia, M., Desai, M., Zhang, J. J., Merritt, J. R., Appell, K. C., Henderson, I. M., & Webb, M. L. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.08.019 · Cited by 33
An apparent paradox: Chemokine receptor agonists can be used for anti-inflammatory therapy
Ali, S., O’Boyle, G., Mellor, P., & Kirby, J. A. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2006.08.011 · Cited by 28
Chu, Y., Yang, X., Xu, W., Wang, Y., Guo, Q., & Xiong, S. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0296-1 · Cited by 24
Self-citation
Cited by
Bachelerie, F., Ben-Baruch, A., Burkhardt, A. M., Combadiere, C., Farber, J. M., Graham, G. J., Horuk, R., Sparre-Ulrich, A. H., Locati, M., Luster, A. D., et al. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.007724 · Cited by 850
β-arrestin- but not G protein-mediated signaling by the “decoy” receptor CXCR7
Rajagopal, S., Kim, J., Ahn, S., Craig, S., Lam, C. M., Gerard, N. P., Gerard, C., & Lefkowitz, R. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912852107 · Cited by 600
Bendinelli, P., Matteucci, E., Dogliotti, G., Corsi, M. M., Banfi, G., Maroni, P., & Desiderio, M. A. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22274 · Cited by 441
Immune regulation by atypical chemokine receptors
Nibbs, R. J. B., & Graham, G. J. (2013) · Nature Reviews Immunology · doi:10.1038/nri3544 · Cited by 407
CXCL12 (SDF1α)-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies?
Duda, D. G., Kozin, S. V., Kirkpatrick, N. D., Xu, L., Fukumura, D., & Jain, R. K. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2636 · Cited by 395
Metadata
- Authors
- Zabel, B. A., Wang, Y., Lewén, S., Berahovich, R. D., Penfold, M. E. T., Zhang, P., Powers, J., Summers, B. C., Miao, Z., Zhao, B., Jalili, A., Janowska-Wieczorek, A., Jaen, J. C., & Schall, T. J.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-09-01
- Volume
- 183
- Issue
- 5
- Pages
- 3204-3211
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2123792735
- Cited by
- 294
- References
- 28
- FWCI
- 11.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.